The lancet 4.2022
Cancer care: beyond survival, Improved models of care for cancer survivors

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00306-3/fulltext

facts:
IOM stated survivorship care agenda:
1. reduce recurrence, new cancer and late effects from Tx
2. survellance
3. Side effect management
4. Coordination with PCP

Take-home:
Routine holistic assessment of needs

NEJM 4.14/2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Pfizer drug
facts:
1. nirmatrelvir plus ritonavir risk reduction 89%, symptomatic high risk covid-19

take-home:
Another pfizer antiviral? still has drug interaction issue. 和現在的Paxlovid 差不多。